Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

tivantinib (ARQ 197)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo, Kyowa Kirin, Merck (MSD)

Drug class:

c-MET inhibitor

Related drugs:

‹

›

MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	erlotinib + ARQ 197 Sensitive: C3 – Early Trials erlotinib + ARQ 197 Sensitive : C3	erlotinib + ARQ 197 Sensitive: C3 – Early Trials erlotinib + ARQ 197 Sensitive : C3
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	ARQ 197 Sensitive: C3 – Early Trials ARQ 197 Sensitive : C3	ARQ 197 Sensitive: C3 – Early Trials ARQ 197 Sensitive : C3
GMNN overexpression	Hepatocellular Cancer	GMNN overexpression	Hepatocellular Cancer	ARQ 197 Sensitive: D – Preclinical ARQ 197 Sensitive : D	ARQ 197 Sensitive: D – Preclinical ARQ 197 Sensitive : D
RRM2 overexpression	Hepatocellular Cancer	RRM2 overexpression	Hepatocellular Cancer	ARQ 197 Sensitive: D – Preclinical ARQ 197 Sensitive : D	ARQ 197 Sensitive: D – Preclinical ARQ 197 Sensitive : D
CDC20 overexpression	Hepatocellular Cancer	CDC20 overexpression	Hepatocellular Cancer	ARQ 197 Sensitive: D – Preclinical ARQ 197 Sensitive : D	ARQ 197 Sensitive: D – Preclinical ARQ 197 Sensitive : D